Navigation Links
Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
Date:6/2/2011

BOULDER, Colo., and PLEASANTON, Calif., June 2, 2011 /PRNewswire/ -- Clovis Oncology, Inc. and Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that they have entered into an agreement to develop an in vitro PCR (Polymerase Chain Reaction) based companion diagnostic test. The goal is to identify activating epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC), including the EGFR T790M mutation.  

"Once again we are able to demonstrate Roche's expertise in Personalized Healthcare. Our agreement with Clovis Oncology strengthens our position as the partner of choice for the development of companion diagnostics. Roche hopes that through this collaboration we will be able to advance oncology diagnostic testing and drug therapy for the benefit of many patients world-wide," said Paul Brown, Head of Roche Molecular Diagnostics.

Patrick Mahaffy, President and CEO, Clovis Oncology added: "We are very pleased to partner with Roche, a clear leader in the development, manufacturing and marketing of companion diagnostic tools.  By incorporating a companion diagnostic during clinical and commercial development of CO-1686, we reinforce our commitment to focus development programs on specific subsets of cancer populations that are most likely to benefit from our targeted therapies."

About CO-1686

CO-1686 is currently in pre-clinical development for advanced NSCLC patients.  CO-1686 has been designed to target and covalently bind to the activating and T790M mutant forms of EGFR.  It does so while also sparing wild-type (normal) EGFR and may thus treat refractory NSCLC while minimizing dose-limiting side effects.   CO-1686 was licensed to Clovis Oncology from Avila Therapeutics, Inc.

About the cobas 4800 system

The cobas EGFR mutation assay will run on the Roche cobas 4800 System, a platform designed to deliver new standards in laboratory testing efficiency and medically relevant diagnostic information.  Cobas 4800 was recently approved in the US and all countries accepting a CE mark for use with the HPV test.

About Clovis Oncology, Inc.

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. The Company is headquartered in Boulder, Colorado, and has additional offices and laboratories in San Francisco and Cambridge, England.  For more information about Clovis Oncology, please visit the Company's website at www.clovisoncology.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

For Clovis Oncology
Anna Sussman / Breanna Burkart
Scout Investor Relations
+1 303 907 5358 or +1 303 907 5162
anna@scoutir.com or breanna@scoutir.com

For Roche
Media Hotline 888-545-2443

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Clovis Oncology, Inc.; Roche Molecular Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Florida Hospital First U.S. Site to Adopt New Automated Laboratory Solution From Roche
2. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
3. Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
4. Rochester Medical Reports Second Quarter Results
5. Rochester Medical Announces Second Quarter 2011 Earnings Conference Call Thursday, May 5, 2011
6. Roche Launches EMR Interface for VA to Facilitate Diabetes Management
7. Rochester Medical Completes Acquisition of Laprolan
8. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
9. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
10. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
11. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Calif. , Mar 29, 2017  Providence ... technology, announced the addition of two industry veterans ... has joined the company to lead Global ... International leadership.  Together, Mr. Lynch and Mr. Scott ... Mr. Lynch joins the company ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care Management ... new PhRMA report on patient out-of-pocket spending: ... and Medicaid Services (CMS), the average amount spent out-of-pocket ... of drug spending in 2016, down from 23% in ... pricing problem, not a coverage problem. Health plans don,t ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... 30, 2017 , ... AudioEducator, a leader in training conferences ... Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, JD., ... to prevent readmissions in light of the most recent programs at the Centers ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced ... dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a member ... including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture renovators, ...
(Date:3/29/2017)... ... ... Full Contact K9, an Atlanta-based dog services provider, has recently teamed up ... owners in creating legally-enforceable pet trusts for their canine companions. , Therilus, a ... their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When our clients ...
(Date:3/29/2017)... ... , ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program ... students who have participated in the program every summer. The 2017 Serve, Learn, ... for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent ...
(Date:3/29/2017)... Florida (PRWEB) , ... March 29, 2017 , ... ... be hosting several educational opportunities for attending prescribers at the upcoming World Congress, ... Network said, “A4M has always been recognized as the visionary leader in the ...
Breaking Medicine News(10 mins):